Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis... Show more
TRVI saw its Momentum Indicator move above the 0 level on November 26, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned positive. In of the 89 cases, the stock moved higher in the following days. The odds of a move higher are at .
The Moving Average Convergence Divergence (MACD) for TRVI just turned positive on November 26, 2025. Looking at past instances where TRVI's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TRVI advanced for three days, in of 274 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 162 cases where TRVI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TRVI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
TRVI broke above its upper Bollinger Band on November 26, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. TRVI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.913) is normal, around the industry mean (27.168). P/E Ratio (0.000) is within average values for comparable stocks, (52.496). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.897). Dividend Yield (0.000) settles around the average of (0.048) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (334.447).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
a developer and manufacturer of neurological products
Industry Biotechnology
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| TSNRX | 20.99 | 0.21 | +1.01% |
| Touchstone Sands Capital Select Gr R6 | |||
| TLGCX | 9.90 | 0.09 | +0.92% |
| Timothy Plan Large/Mid Cap Growth C | |||
| FTADX | 58.37 | 0.43 | +0.74% |
| Fidelity Advisor International Discv M | |||
| ACEAX | 10.52 | 0.02 | +0.19% |
| AB All China Equity A | |||
| JRBFX | 30.10 | -0.09 | -0.30% |
| JHancock Regional Bank I | |||
A.I.dvisor indicates that over the last year, TRVI has been loosely correlated with BIESF. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if TRVI jumps, then BIESF could also see price increases.
| Ticker / NAME | Correlation To TRVI | 1D Price Change % | ||
|---|---|---|---|---|
| TRVI | 100% | -0.75% | ||
| BIESF - TRVI | 43% Loosely correlated | N/A | ||
| PTGX - TRVI | 38% Loosely correlated | -0.08% | ||
| QURE - TRVI | 30% Poorly correlated | -0.43% | ||
| XENE - TRVI | 29% Poorly correlated | +0.52% | ||
| ABSI - TRVI | 28% Poorly correlated | +2.59% | ||
More | ||||